Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Price Target at $7.25

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $7.25.

Several analysts have weighed in on MIST shares. Wells Fargo & Company lowered their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a research note on Friday, April 10th. They set a “strong-buy” rating and a $6.00 target price for the company. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th.

Milestone Pharmaceuticals Price Performance

Shares of NASDAQ:MIST opened at $1.41 on Tuesday. The company has a current ratio of 9.18, a quick ratio of 9.09 and a debt-to-equity ratio of 1.61. The company has a fifty day simple moving average of $1.67 and a 200 day simple moving average of $1.91. The firm has a market cap of $175.55 million, a PE ratio of -2.07 and a beta of 1.04. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The company had revenue of $0.24 million for the quarter, compared to analyst estimates of $30.12 million. On average, equities research analysts anticipate that Milestone Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Insider Activity

In other news, CEO Joseph Oliveto sold 36,500 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the completion of the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Creative Planning lifted its holdings in Milestone Pharmaceuticals by 74.6% in the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Milestone Pharmaceuticals by 30.1% in the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after acquiring an additional 10,000 shares during the last quarter. Bay Rivers Group raised its holdings in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares during the period. Strategic Family Wealth Counselors L.L.C. acquired a new stake in Milestone Pharmaceuticals during the 4th quarter worth about $25,000. Finally, Eaton Financial Holdings Company LLC acquired a new stake in Milestone Pharmaceuticals during the 4th quarter worth about $26,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.